

Direct-Acting Antivirals for Hepatitis C Prior Authorization Form

Index: **MED**

Office of the Medical Director PO Box 44321 Olympia WA 98504-4321

How to submit your request:

- State Fund: Fax completed form along with supportive medical documentation to 360-902-6315
 Attention: Drug Review Program.
- Self-Insurance: Contact the self-insurer or their third-party administrator.

Injured Worker		Claim Number			
Pharmacy Name		Telephone Number	Fax Number		
Prescriber		Telephone Number	Fax Number		
Select a Treatment Regimen for Patient					
	Fibrosis Score:	Regiment for Fatient			
Severity of Liver Disease	F0				
	Treat as compensated cirrhosis:				
	F4 (well compensated)				
	Treat as decompensated cirrhosis:				
	F4 (previously decompensated, now compensated with medication)				
	F4 (chronically decompensated)				
Treatment Regimen	Mavyret				
	Epclusa (for decompensated cirrhosis)				
	☐ Vosevi (for FDA-approved indications)				
	☐ Other:				
Treatment Duration	8 weeks	12 weeks	Other:		
1. Patient's genotype:		Date of lab:			
2. Date of patient's initial positive test for HCV antibody:		3. Date of patient's initial HCV RNA viral load:			
4. Patient's current HCV RNA viral load:		Date of lab:			
4. I alient 3 current HOV KNA Vital load.		But of lab.			
5. What were past transmission risk factors?		During what time periods?			
	usly been treated for Hepatitis C?	l			
☐ Yes ☐ No					
If yes, what was the treatment?		Treatment dates:			
Was the treatment completed?		If no, why not?			
Yes No 7. Has patient had NS5A or NS3 resistance-associated variant (RAV) testing?					
Yes No					

8. Provide the follow	8. Provide the following for APRI scoring:						
AST level:	I	Date taken:		Upper normal:			
Platelet count:		Date taken:					
9. Provide the following for CPT scoring:							
Ascites:	☐ Absent	☐ Slight	☐ Moderate	Date determined:			
Encephalopathy:	☐ None	Grade 1—2	☐ Grade 3—4	Date determined:			
Albumin level:				Date taken:			
Total bilirubin level:				Date taken:			
INR value:				Date taken:			
10. What is patient's creatinine clearance (CrCl or eGFR)?							
11. Has patient had an organ transplant or is awaiting an organ transplant? ☐ Yes ☐ No							
12. Are there any possible drug interactions, including prescription and OTC drugs, which could hinder successful hepatitis C treatment (proton pump inhibitors, amiodarone, statins, HIV antivirals, anticonvulsants, antifungals, antimycobacterials, or other CYP substrates/inducers/inhibitors)? \[\textstyle \textst							
13. Does patient have any contraindications to ribavirin, such as pregnancy or planning on becoming pregnant, sickle cell anemia, thalassemia major or anemia? ☐ Yes ☐ No							
14. Does patient have any condition that would prevent them from receiving long term clinical benefit from HCV treatment?							
☐ Yes ☐ No							
If yes, please explain:							
Has patient been told of the risks and benefits of antiviral therapy, told the importance of adherence to treatment, and evaluated for psychosocial readiness for treatment? ☐ Yes ☐ No							
16. Are you a participant in Project ECHO?							
☐ Yes ☐ No							
If yes, please provide a copy of the consultation notes.							
Please provide the following documentation for your patient:							
 Current HCV HCV antibod Genotype lat RAV testing Albumin, tota 	RNA viral load RNA viral load y test	es					

Date

Prescriber Specialty

Prescriber Signature